PMID: 7470733Jan 1, 1980Paper

Absence of changes in drug disposition and catecholamine sensitivity in the hyperthyroid dog

British Journal of Pharmacology
T Ishizaki, K Tawara


1 In order to study the relative contribution of hepatic drug metabolizing enzymes and hepatic blood flow to the clearance of drugs in the hyperthyroid state, the disposition kinetics of two model compounds (antipyrine and propranolol) were examined in thyroid-fed dogs as compared to euthyroid and phenobarbitone-pretreated animals. 2 In hyperthyroid dogs, the possibility of catecholamine hypersensitivity was evaluated by assessing the chronotropic response to isoprenaline and by constructing a drug concentration-effect (beta-blockade) relationship. 3 The plasma propranolol half-life (0.97 +/- 0.12 h) of the hyperthyroid animals did not differ significantly from either the euthyroid group or the phenobarbitone-pretreated group. This was observed with no significant change in the apparent volume of distribution among the three experimental groups. 4 Phenobarbitone pretreatment accelerated significantly the elimination of antipyrine (half-life, 1.09 +/- 0.15 h, P less than 0.01) as compared to the euthyroid (2.84 +/- 0.35 h) and the hyperthyroid groups (2.58 +/- 0.13 h), respectively, without any changes in the apparent volume of distribution in any group. 5 Neither the chronotropic responses to exogenously administered catecholam...Continue Reading


Jan 1, 1976·Clinical Pharmacokinetics·A S NiesG R Wilkinson
Feb 1, 1977·British Journal of Clinical Pharmacology·J M BellD G McDevitt
Jan 1, 1977·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·R Kato
Jun 1, 1978·Circulation·D J GreenblattD H Huffman
Oct 1, 1978·British Journal of Clinical Pharmacology·D G McDevittD A Montgomery
Jan 1, 1978·Biochemical Pharmacology·R C RumbaughH D Colby
Feb 15, 1979·The New England Journal of Medicine·S RubenfeldP O Kohler
Jan 1, 1976·Clinical Pharmacokinetics·M Eichelbaum
Jan 1, 1975·Clinical Pharmacology and Therapeutics·E S VesellC A Shively
Jan 1, 1976·The Journal of Clinical Endocrinology and Metabolism·P SaengerM I New
Feb 1, 1976·Journal of Pharmacokinetics and Biopharmaceutics·C F GeorgeC T Dollery
May 1, 1974·Journal of Clinical Pharmacology·S F BrunkW R Wilson
Dec 1, 1965·British Journal of Pharmacology and Chemotherapy·J W BlackR G Shanks
Sep 1, 1974·The Journal of Clinical Endocrinology and Metabolism·R H Noth, S W Spaulding
Sep 1, 1974·The Journal of Clinical Endocrinology and Metabolism·Y NishizawaK Okuda
Mar 1, 1973·The Journal of Clinical Endocrinology and Metabolism·S S StofferG M Pikler
May 9, 1974·The New England Journal of Medicine·M EichelbaumH J Dengler
Mar 20, 1969·The New England Journal of Medicine·A H Conney
Dec 1, 1969·The Journal of Clinical Investigation·E S Vesell, J G Page
Jan 1, 1970·Clinical Pharmacology and Therapeutics·D G ShandJ A Oates
May 1, 1969·British Journal of Pharmacology·D Dunlop, R G Shanks
May 1, 1966·Clinical Pharmacology and Therapeutics·G Levy
Apr 1, 1964·Physiological Reviews·T S HARRISON
Feb 1, 1962·British Journal of Pharmacology and Chemotherapy·R KATO, E CHIESARA
Aug 1, 1950·The Journal of Clinical Investigation·J D MYERSB C HOLLAND
Jan 1, 1949·The Biochemical Journal·D K Chaudhuri, E Kodicek

❮ Previous
Next ❯


Feb 1, 1981·European Journal of Clinical Pharmacology·K TawaraS Yoshida
Sep 1, 1981·Journal of Autonomic Pharmacology·A Gibson
Jan 1, 1987·Pharmacology & Therapeutics·G C Farrell

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.